載入中
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
前收盤價
US$2.53
−US$0.05 · -1.94%
盤中時間採用ET。市場資料可能有所延遲。
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
日內區間
目前US$2.53
52週區間
目前US$2.53
盤中時間採用ET。市場資料可能有所延遲。
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
日內區間
目前US$2.53
52週區間
目前US$2.53
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 125.1萬 USD | 108.6萬 USD | — | — | — |
| 毛利 | −125.1萬 USD | −108.6萬 USD | — | — | — |
| 研究與開發 | 4484.5萬 USD | 5526.7萬 USD | 4263.7萬 USD | 3715.9萬 USD | 1927.8萬 USD |
| 銷售、一般及管理費用 | 1870.7萬 USD | 1800萬 USD | 1215.9萬 USD | 931萬 USD | 602.3萬 USD |
| 營業費用 | 6230.1萬 USD | 7218.1萬 USD | 5479.6萬 USD | 4646.9萬 USD | 2530.1萬 USD |
| 利息收入 | 535.7萬 USD | 789.2萬 USD | 528.2萬 USD | 66.8萬 USD | 9.6萬 USD |
| 折舊和攤銷 | 125.1萬 USD | 108.6萬 USD | 95.7萬 USD | 94.2萬 USD | 68.2萬 USD |
| 營業利益 | −6355.2萬 USD | −7326.7萬 USD | −5479.6萬 USD | −4646.9萬 USD | −2530.1萬 USD |
| 淨利 | −5819.7萬 USD | −6536.3萬 USD | −4943.4萬 USD | −4590.1萬 USD | −2521萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
